Concerning defining genetic abnormalities, the WHO-5 classification recognizes three distinct groups, such as MDSs with low blasts and isolated 5q deletion (MDS-5q) and MDSs defined by a molecular alteration [1,38], such as SF3B1 mutations (MDS-SF3B1) [1,39,40] and biallelic TP53 inactivation (MDS-biTP53) [1,45]. This evidence concerns the gene SF3B1 and myelodysplastic syndrome.